EFB Dengue Literature Review

GC-Independent Response

10 min read

GC-Independent Response

Overview

A GC-independent response is a B cell response that did not transit a germinal centre. This is a claim about origin. It is distinct from — and much weaker than — the claim that a response was extrafollicular, which is a claim about anatomical location (see Extrafollicular Response).

The wiki holds these as separate pages because the distinction determines what can be concluded from peripheral blood, which is the only compartment most human studies — including every dengue study in this wiki — can sample. The distinction was made explicit and given consensus weight by Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, a twelve-author Immunity Perspective which concluded that the label “EF” should be reserved for responses whose extrafollicular location has been directly imaged, and that other terms — “non-GCB”, “primary non-GCB”, “secondary non-GCB” — should be used when only origin is known.

The operative rule for this wiki:

Evidence availableLicensed claimNot licensed
Blood flow cytometry phenotype aloneNeither, on its ownBoth
Blood phenotype + low SHM + clonal connectivity to naive precursors + transcriptional identity with cells in GC-devoid tissueGC-independent (by inference, probabilistic)Extrafollicular
GC-ablation genetics (e.g. TLR7 gain-of-function mice, Bcl6 knockouts) with a preserved antibody responseGC-independent (strong)Extrafollicular
Tissue imaging of antigen-specific B cell proliferation outside a follicleExtrafollicular—

Note the asymmetry: an EF response is necessarily GC-independent, but a GC-independent response is not necessarily extrafollicular. It may occur at the T-B border, in the interfollicular zone, at the subcapsular sinus, or at a site not yet identified — all of which Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses flags as candidate locations for human DN2 generation that have never been visualised.

Key Points from Literature

  • The distinction is the paper’s central corrective, and it is applied by name to the human DN2 cell. GC-independent derivation of DN2 is described as suggested by severe-COVID tissue studies and lupus-nephritis kidney biopsies, but “direct visualization of EF foci with DN2 cells in the splenic bridging channel or LN medullary cords has not been done.” The concluding sentence: “the EF designation of this human DN2 cell refers to its presumed GC-independent origin rather than its location.” (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • No flow cytometry marker set alone establishes either claim. “Currently there are no flow cytometry-based means alone that can distinguish EF B cells nor their progeny from activated cells in earlier phases.” Absent CXCR5, low SHM, low BCR affinity and IgM isotype are each individually non-definitive because each can be found on cells that did participate in a GC (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses).

  • GC-independent responses can be T-dependent. T-dependent but Tfh-independent antibody responses are documented; acute influenza and SARS-CoV-2 in mice induce T-dependent, GC-independent, high-avidity, long-lived responses in structurally intact lymph nodes, where the site of B cell selection is simply unknown (Eisenbarth “situation 2B”). GC-independence therefore cannot be inferred from T-independence, nor T-independence from GC-independence (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses).

  • GC-independent responses produce long-lived output. Both GC and GC-independent pathways generate plasmablasts, memory B cells, and short- and long-lived plasma cells; they differ in kinetics and relative contribution, not in the categories of cell produced. Recent lineage-tracing work shows GC-independent antibodies dominating the first month after primary immunisation — including high-affinity antibodies without significant affinity maturation — before GC-derived antibodies take over (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses; consistent with Cancro2020 - Age-Associated B Cells, review, and Song2022 - Tfh Outside Germinal Centers Drive T-bet CD11c B Cells, mouse fate-mapping).

  • Mutational load gives a probability of GC participation, not a determination. Mutational content is the product of SHM rate and time; the rate is rarely measured. One direct measurement in autoimmune mice found the GC-independent SHM rate comparable to a GC response after NP immunisation — load differs because GC responses last longer and repeatedly re-engage CD40–CD40L, sustaining AID. In prolonged responses (MRL/lpr, chronic Salmonella) GC-independent mutational load approaches GC levels. AID expression is likewise non-diagnostic, being required for class switching, which precedes GC entry (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, Figure 2; see also Somatic Hypermutation, William2002 - Extrafollicular Somatic Hypermutation in Autoimmune Mice, mouse).

  • The strongest GC-independence evidence in the wiki is genetic, not phenotypic. Human TLR7 gain-of-function mutations cause SLE with expanded ABC/DN2 in a B cell-intrinsic, GC-independent fashion, and the orthologous mouse mutation induces lupus without GC involvement (see Sanz2025 - Human Atypical B Cells Overview, review citing Brown et al. 2022). Under the Eisenbarth framework this is a licensed origin claim; it says nothing about location.

  • Tissue evidence for GC-independence in acute human infection exists and is architectural. Post-mortem COVID-19 lymph nodes and spleens showed complete GC absence with preserved FDC networks and a specific block in Bcl-6⁺ GC-Tfh differentiation, with AID⁺ B cells distributed diffusely outside GC structures (see Kaneko2020 - GC Loss and TFH Block in COVID-19, n=11 COVID + controls, multi-color immunofluorescence). This licenses “GC-independent” for that cohort’s response; it does not by itself locate the response at a classical EF site.

  • Mechanistic programme evidence is origin evidence, and survives the location caveat intact. The TLR7 + IFN-γ + IL-21 differentiation cascade, ZEB2/T-bet transcriptional programme, CD40L antagonism, and clonal connectivity between activated naive cells, DN2 and ASCs are all claims about how a cell was made, not where (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, cross-sectional + in vitro + multi-omic; Scharer2019 - Epigenetic Programming in SLE B Cells, n=9 SLE + n=12 HC; Tipton2015 - ASC Diversity and Origin in SLE, n=5 SLE acute flare).

  • Process-based labels proposed for use when location is unknown (annotation layer — the wiki retains its existing page names): activated naive → “primary non-GCB”; DN1 → “memory GCB” or “memory non-GCB” as evidence warrants; DN2 → “primary switched non-GCB”; effector/activated memory → “secondary non-GCB”; and generic “non-GCB” where GC-independence is claimed without spatial data. The criteria used to establish GC-independence should be stated in each case (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses).

  • ★ [2026-08-27] Worked example — applying the evidence-to-claim test to a paper whose title asserts the location claim. Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues is titled “Extrafollicular … DN3 B cells infiltrate inflamed tissues”. Scoring it against the criteria on this page:

    Evidence the paper presentsClaim it licenses
    DN cells present in COVID-19 thoracic lymph nodes (18–66% of CD19⁺ B cells, n=6)Presence only. No follicular-vs-extrafollicular quantification is performed; anti-Bcl6 (clone LN22) is in the antibody list and no Bcl6 result is reported anywhere in the paper. The EF location criterion is not met.
    DN3 infiltrating lung parenchyma and salivary glandNot an EF claim. A B cell in an end organ is trivially outside a follicle; tissue infiltration ≠ participation in an EF focus in a secondary lymphoid organ.
    DN3 transcriptome resembles ASC precursors; DN3 tracks plasmablasts (r = 0.66, n=38)Consistent with a GC-independent effector pathway, but inferential — no mutational load, GC-ablation, or clonal-connectivity evidence.
    (External) Kaneko2020 - GC Loss and TFH Block in COVID-19 found Bcl-6⁺ Tfh and GC loss in the same autopsy cohortThe strongest GC-independence argument available — by exclusion — and it belongs to Kaneko, not to this paper. Cite it there.

    The lesson generalises: a paper can carry “extrafollicular” in its title, be widely relayed as tissue-level EF evidence, and still rest entirely on a presumed origin (see Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues, n=38 blood + n=6–10 tissue).

  • [2026-08-27] Tissue evidence can strengthen a GC-independence claim without ever imaging a focus — if a companion study has ruled out germinal centres in the same specimens. The COVID-19 autopsy lymph nodes here are the same rapid-autopsy series in which Kaneko2020 - GC Loss and TFH Block in COVID-19 documented loss of germinal centres and Bcl-6⁺ Tfh cells. B cells accumulating in a lymph node with no germinal centres cannot readily be GC-derived. This is the strongest form of GC-independence argument realistically obtainable from human tissue — and it requires the companion study, which most tissue papers lack (see Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues with Kaneko2020 - GC Loss and TFH Block in COVID-19, n=6 autopsy).

Contradictions & Debates

  • Is GC-independence itself established for human DN2, or only suggested? Eisenbarth uses “suggested” and “presumed” throughout, resting the claim on two tissue studies (severe COVID, lupus nephritis kidney biopsies) plus transcriptional identity. Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection pushes further in the other direction: in malaria-exposed and vaccinated donors, all non-naive clusters including the T-bet⁺CD11c⁺ “alternative lineage” showed significant SHM consistent with post-GC origin, and no cluster upregulated PC maintenance genes. On that reading, in non-SLE contexts even the origin claim is contested — not merely the location claim. The wiki holds both: GC-independence is well supported in TLR7-high pathological settings and is genuinely uncertain in vaccination and chronic-infection settings.
  • Does the distinction have teeth for a study that can only sample blood? Eisenbarth prescribes tissue imaging and acknowledges it is “usually infeasible” for human work, offering no alternative method beyond stating criteria precisely. A defensible reading is that the framework tells human blood studies what they may not claim without telling them how to claim more. The wiki’s response is the table above: use converging origin evidence, and do not use the word “extrafollicular.”
  • Where does the T-B border sit? The Eisenbarth authors explicitly failed to reach consensus on whether phase 2 (proliferation at the T-B border, interfollicular zone, or subcapsular sinus) should be called extrafollicular. If it should, some responses currently labelled merely GC-independent would be EF; if it should not, the classical EF sites (bridging channel, red pulp, medullary cords) remain a narrower category than the wiki has historically implied. This is unresolved in the primary literature and is recorded here rather than decided.

Sources

Graph View

Backlinks